BioPharmSignal logoBioPharmSignal

Biotech News

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

GH Research (GHRS)GH ResearchEarnings

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025 DUBLIN,

Related news

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-08-04 20:00 EST

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

NGENNervGen Pharma2026-08-13 11:30 EST

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

ANNXAnnexon, Inc.2026-08-12 10:05 EST

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

View all latest news

GH Research

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals...

Recent company news

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GHRSGH Research2026-04-29 12:00 EST

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GHRSGH Research2026-04-20 13:00 EST

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Stock data

Close
28.33 USD
Market cap
1.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States